MedImmune Looking For Multi-Purpose Biologics For Metabolic Diseases
This article was originally published in The Pink Sheet Daily
Coming in from University of Chicago, Christopher Rhodes is heading up cardiovascular and metabolic research, with a goal to find biologic candidates that act early in the cascade of events across a range of disease issues.
You may also be interested in...
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.